Abstract: A stent comprising a degradable metal stent main body; a partition layer which is applied to the surface of the stent main body so that at least parts of the surface of the luminal side are not covered; and an agent-containing layer which is applied to the surface of the partition layer at least partially on the abluminal side of the stent main body and comprises one or more agents and possibly one or more polymers.

Abstract: A method for producing an agent depot for mechanical connection to a surface of an endovascular implantable body, comprising a) providing one or more polymers; b) providing one or more agents; and c) producing an agent depot from said polymers and said agents, the agent depot being mechanically connectable to the surface of the body using force action or adhesive.

Abstract: An x-ray marker for medical implants made of a biocorrodible metallic material, the x-ray marker comprises a boride or carbide of the elements tantalum or tungsten.

Abstract: A stent made of a biocorrodible metallic material and having a coating or cavity filling which contains genistein.

Abstract: An x-ray marker for medical implants made of a biocorrodible metallic material, wherein the x-ray marker composite comprises 1-40 weight parts of a carrier matrix having a melting point greater than or equal to 43° C., which comprises 90 weight-percent or more triglycerides; and 60-99 weight parts of a radiopaque marker component, which is embedded in the carrier matrix.

Abstract: The invention relates to a radio-opaque marker for medical implants. Said marker contains between 10 and 90 weight percent of a biodegradable base component, between 10 and 90 weight percent of one or more radio-opaque elements from the group containing I, Au, Ta, Y, Nb, Mo, Ru, Rh, Ba, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Hf, Ta, W, Re, Os, Ir and Bi as a marker component and 10 weight percent oF residual components, the aforementioned components amounting to 100 weight percent.

Abstract: A method of treating a patient includes the medical use of one or more of the elements from the group yttrium, neodymium and zirconium, pharmaceutical formulations which contain said elements and implants which are at least region-wise made up of such formulations. It has been found inter alia that a formulation containing one or more of the elements has an action of inhibiting the proliferation of human smooth muscle cells.

Abstract: A stent comprises a tubular base body which is open on the front sides thereof and has a peripheral wall that is at least partially covered with a coating system consisting of at least one polymer carrier and at least one pharmacologically active substance, which is released into the surrounding tissue once the stent has been implanted in the human or animal body. The invention creates a coating system which enables an optimum local application of the active ingredient. A concentration of the substance, a morphological structure of the carrier(s), a material modification of the carrier(s), and/or a layer thickness of the carrier(s), are predetermined in the longitudinal direction of the stent, in such a way that the elution varies locally in the longitudinal direction of the stent and is determined according to the pathophysiological and/or rheological conditions to be expected during the application.

Abstract: The invention concerns an endovascular implant comprising a biodegradable material and having a tubular main body which is open at the ends and which is dilatable from an unexpanded condition into an expanded condition. The implant is so designed that when the implant in the expanded condition is subjected to a radially acting compression pressure in the range of between 5 and 30 kPa (0.05-0.3 bar) a cross-sectional area of the implant is reduced to 70% or less of the original cross-sectional area, or an internal volume of the implant is reduced to 70% or less of the original internal volume.

Abstract: An endoprosthesis, in particular an intraluminal endoprosthesis such as a stent, comprises a carrier structure, which includes at least one component comprising a magnesium alloy of the following composition: Rare earth metals: between about 2.0 and about 5.0% by weight, with neodymium between about 1.5 and about 3.0% by weight Yttrium: between about 3.5% and about 4.5% by weight Zirconium: between about 0.3% and about 1.0% by weight Balance: between 0 and about 0.5% by weight wherein magnesium occupies the proportion by weight that remains to 100% by weight in the alloy.

Abstract: An endoprosthesis, in particular an intraluminal endoprosthesis such as a stent, comprises a carrier structure, which includes at least one component comprising a magnesium alloy of the following composition: Magnesium: between about 60.0 and about 88.0% by weight Rare earth metals: between about 2.0 and about 30.0% by weight Yttrium: between about 2.0% and about 20.0% by weight Zirconium: between about 0.5% and about 5.0% by weight Balance: between 0 and about 10.0% by weight wherein the alloy components add up to 100% by weight.

Abstract: The invention concerns inter alia an implant for vessel ligature, the implant which comprises an alloy, wherein the alloy is at least partially biodegradable, and wherein the alloy comprises: greater than 87% magnesium; from about 3% to about 6% yttrium; from about 1% to about 5% lanthanide; and a balance of about 0.0% to about 2%.

Abstract: A stent, in particular a coronary stent, comprising at least two tubular portions which are arranged adjacently in the longitudinal direction of the stent and which comprise a plurality of interconnected, substantially cell-shaped elements which have an orientation and are connected together in the longitudinal direction of the stent by way of at least one first connecting means, wherein the elements are of such an arrangement and/or configuration that the ends of the elements which are in the longitudinal direction of the stent define an edge contour extending around the stent in a wave-like configuration in the peripheral direction thereof, and wherein the mutually adjoining edge contours of two tubular portions extend around the stent substantially in in-phase relationship.

Abstract: The invention concerns an endoprosthesis comprising a carrier structure which contains a metallic material wherein the metallic material contains a magnesium alloy of the following composition: magnesium: >90%, yttrium: 3.7%-5.5%, rare earths: 1.5%-4.4% and balance: <1%.

Abstract: A stent, in particular a coronary stent, comprising at least two tubular portions (8) which are arranged adjacently in the longitudinal direction of the stent (1) and which comprise a plurality of interconnected, substantially cell-shaped elements (10) which have an orientation and are connected together in the longitudinal direction of the stent (1) by way of at least one first connecting means (20), wherein the elements (10) are of such an arrangement and/or configuration that the ends of the elements (10) which are in the longitudinal direction of the stent define an edge contour (36, 37, 38) extending around the stent in a wave-like configuration in the peripheral direction thereof, and wherein the mutually adjoining edge contours (36, 37) of two tubular portions (8) extend around the stent substantially in in-phase relationship.